gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · NUVBHealthcarePharmaceuticals

Nuvation Bio Inc. (NUVB)

$4.73+0.85%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$4.73▼ 2.07% in range
Nov 4, 2025Low $4.05 · High $9.54Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Nuvation Bio closed at $4.73 on Nov 4, up 0.85%, 50.4% below its 52-week closing high. Volume of 8.4M shares was 1.67× its 20-day average (above normal).

Split-adjusted performance: -3.1% over one month, -6.2% over six months, -8.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $31.69M, up 555.6% from a year earlier, with a net margin of -198.3%.

Short interest was 63.2M shares at the Oct 15 settlement, up 7.4% from the prior report (23.9% of float, 9.7 days to cover).

Market cap$1.66B351.1M shares
Revenue · quarter$31.7M+555.6% YoY
Diluted EPS$-0.18—
P/E · TTM—P/S 9.8×
Net margin-198.3%Gross 73.0%
Dividend yieldNone
52-week range4.05 – 9.54−50.4% from high
Volume8.4M1.67× 20-day avg
Volatility · 60d50.8%Annualised
Short % of float23.9%9.7 days to cover
Net cash$399.4MCash $661.0M
Next earnings—Not scheduled
Split-adjusted performance
1W +3.1%1M −3.1%3M −22.6%6M −6.2%YTD −47.2%1Y −8.5%3Y +373.0%5Y −50.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum67
Revenue growth94
Net margin39
Value (low P/E)—
Size78

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short63.2M+7.4% vs prior
Days to cover9.7Settled Oct 15
% of float23.9%
Short vol. 10d52.3%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
NUVBNuvation Bio$4.73+0.85%−6.2%+555.6%−198.3%—$1.66B
KLRAKailera Therapeutics$12.80+1.75%————$1.66BCompare
ANIPANI Pharmaceuticals$71.65−0.87%−14.8%+25.9%8.6%16.5$1.65BCompare
SUPNSupernus$28.21+0.21%−45.2%+18.0%9.2%—$1.64BCompare
RAREUltragenyx Pharmaceutical$17.16+3.19%−33.8%+28.1%−43.0%—$1.69BCompare
PAHCPhibro Animal Health$39.43+4.73%−32.6%+4.8%5.5%16.1$1.60BCompare
QUREuniQure$23.03−3.52%+0.9%+11.0%−1387.8%—$1.60BCompare
NRIXNurix Therapeutics$15.95−38.23%−5.5%+8426.3%81.7%5.9$1.74BCompare
OCULOcular Therapeutix$7.14+4.69%−26.5%+0.1%−584.5%—$1.57BCompare

News about Nuvation Bio

All news →
Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?The Motley Fool · Jun 29, 2026NeutralVeteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains MomentumThe Motley Fool · Jun 17, 2026▲ PositiveInsider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB)The Motley Fool · Apr 13, 2026NeutralNUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law FirmBenzinga · Mar 21, 2026▼ Negative

Quick answers

What does Nuvation Bio do?
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC).
What is NUVB's market cap?
$1.66B, based on the Nov 4 close of $4.73.
Does Nuvation Bio pay a dividend?
No regular cash dividend has been paid in the last year.
How much of NUVB is sold short?
63.2M shares, 23.9% of float, as of Oct 15, 2026.
What sector is NUVB in?
Healthcare, in the Pharmaceuticals industry.

About Nuvation Bio

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

HQ: New York, NY305 employeesListed Feb 10, 2021nuvationbio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology